» Articles » PMID: 20608970

BRCA1 16 Years Later: Risk-associated BRCA1 Mutations and Their Functional Implications

Overview
Journal FEBS J
Specialty Biochemistry
Date 2010 Jul 9
PMID 20608970
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the tumor suppressor breast cancer susceptibility gene 1 (BRCA1), an important player in the DNA damage response, apoptosis, cell cycle regulation and transcription, confer a significantly elevated lifetime risk for breast and ovarian cancer. Although the loss of wild-type BRCA1 function is an important mechanism by which mutations confer increased cancer risk, multiple studies suggest mutant BRCA1 proteins may confer functions independent of the loss of wild-type BRCA1 through dominant negative inhibition of remaining wild-type BRCA1, or through novel interactions and pathways. These functions impact various cellular processes and have the potential to significantly influence cancer initiation and progression. In this review, we discuss the functional classifications of risk-associated BRCA1 mutations and their molecular, cellular and clinical impact for mutation carriers.

Citing Articles

Public neoantigens in breast cancer immunotherapy (Review).

Sueangoen N, Thuwajit P, Yenchitsomanus P, Thuwajit C Int J Mol Med. 2024; 54(1).

PMID: 38904202 PMC: 11188978. DOI: 10.3892/ijmm.2024.5388.


BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.

Lei G, Mao C, Horbath A, Yan Y, Cai S, Yao J Cancer Discov. 2024; 14(8):1476-1495.

PMID: 38552003 PMC: 11296921. DOI: 10.1158/2159-8290.CD-23-1220.


DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation.

Yan J, Wang S, Zhang J, Yuan Q, Gao X, Zhang N Cancer Biol Med. 2024; 21(3).

PMID: 38164720 PMC: 10976329. DOI: 10.20892/j.issn.2095-3941.2023.0303.


High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.

Zhu L, Pan J, Qian Z, Ye W, Wang X, Cao W Breast Cancer. 2021; 29(1):103-113.

PMID: 34403063 PMC: 8732803. DOI: 10.1007/s12282-021-01286-1.


Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.

Raimundo L, Calheiros J, Saraiva L Cancers (Basel). 2021; 13(14).

PMID: 34298653 PMC: 8303227. DOI: 10.3390/cancers13143438.